The QualityStocks Daily Friday, February 28th, 2025

Today's Top 3 Investment Newsletters

360 Wall Street(ORGO) $6.2100 +102.28%

Premium Stock Alerts(PMAX) $0.5110 +43.54%

MarketClub Analysis(ARBB) $0.6520 +35.83%

The QualityStocks Daily Stock List

Enveric Biosciences (ENVB)

MarketClub Analysis, QualityStocks, INO Market Report, StocksEarning, MarketBeat, Zacks, StockStreetWire, Small Cap Firm, Schaeffer's, Fierce Analyst, 360 Wall Street, StockWireNews, Smartmoneytrading, Premium Stock Alerts and 247 Market News reported earlier on Enveric Biosciences (ENVB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Enveric Biosciences Inc. (NASDAQ: ENVB) (FRA: SLZ) is a patient-focused biotech firm spe-cialized in enhancing the lives of patients who have suffered the adverse effects of undergoing conventional cancer treatment. The firm has a goal of testing different natural compounds, especial-ly cannabinoids, in order to develop novel medicinal formulations that clinicians can prescribe to patients exhibiting symptoms of adverse effects of cancer treatment.

The company, which was founded in 1994 and is headquartered in Naples, Florida relies on its ex-tensive global network of oncologists and scientists to leverage the innovative clinical develop-ments within the cannabinoids space to identify opportunities to come up with cannabinoid-based formulations.

Enveric Biosciences has a pipeline of different products which are in varying stages of develop-ment. For example, its cannabinoid-based formulation for glioblastoma multiforme is in preclinical development, and so is its candidate for radiation dermatitis. Another candidate targeting chemo-therapy-triggered peripheral neuropathy is still in the discovery phase.

At the end of 2020, David Johnson, the Chairman and CEO of the company gave the shareholders of the company an update about the performance of the firm thus far, and he gave highlights of what the company looks to achieve in the years to come, beginning with 2021. In Q1 of 2021, the company acquired an exclusive and perpetual license to five cannabinoid molecules from Diverse Biotech. These will help Enveric Biosciences access scientists and data crucial to the preclinical and clinical development of drugs that can alleviate some side effects of cancer treatment.

Additionally, the firm launched a development collaboration as well as an exclusive supply agree-ment with PureForm Global in the quest of the two firms to speed up the development of formula-tions geared at treating the pain and inflammation caused by cancer treatment.

If those development programs are successful, they will address a massive need by patients to uti-lize plant-based products while managing the different side effects triggered by the existing cancer therapies. Investors are bound to benefit as this demand is met by the products developed by the company.

Enveric Biosciences (ENVB), closed Monday's trading session at $2.8, up 32.0755%, on 12,197,350 volume. The average volume for the last 3 months is 22,610 and the stock's 52-week low/high is $1.13/$28.05.

OneConnect Financial Technology Co. (OCFT)

StreetInsider, QualityStocks, InvestorPlace, Zacks, Wealth Insider Alert, StockEarnings, MarketBeat and FreeRealTime reported earlier on OneConnect Financial Technology Co. (OCFT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OneConnect Financial Technology Co. Ltd (NYSE: OCFT) is a holding firm that is engaged in the provision of online information and operating support services and cloud-platform-based Fintech solutions.

The firm has its headquarters in Shenzhen, the People’s Republic of China and was incorporated in December 2015. Prior to its name change, the firm was known as Ping An Financial Technology Consulting Co. Ltd. It serves consumers in China.

The company is party to a strategic agreement with Hainan Local Financial Supervision Adm., which entails the development of smart supervision and smart financial services in the Hainan free trade port’s financial sector as well as the island province of Hainan. It operates as a Ping An Insur-ance Co. Ltd subsidiary and conducts its businesses mainly within the domestic market. The com-pany serves consumers in the financial services industry, which includes asset management, insur-ance and banking.

The enterprise operates a regulatory solution dubbed Regtech, which helps authorities automate and digitize their operations. It also provides insurance sales management solutions, artificial intel-ligence customer service, asset-liability management, asset management services, auto insurance operations and services, SME and retail banking risk-management services, SME financing and digital retail banking services. In addition to this, the enterprise offers technology infrastructure, including data management and cloud services.

OneConnect Financial Technology Co. (OCFT), closed Monday's trading session at $5.5, up 26.4746%, on 1,413,068 volume. The average volume for the last 3 months is 9,787,516 and the stock's 52-week low/high is $0.8651/$5.68.

Auxly Cannabis Group (CBWTF)

InvestorPlace, QualityStocks, The Wealth Report, Wealth Insider Alert, MarketBeat, Wolf of Penny Stocks, TopStockAnalysts, The Online Investor, StockEarnings, ProTrader, Penny Picks, Epic Stock Picks and Damn Good Penny Picks reported earlier on Auxly Cannabis Group (CBWTF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Auxly Cannabis Group Inc. (OTCQX: CBWTF) (TSE: XLY) (FRA: 3KF) is a consumer-packaged goods firm that is engaged in the development, manufacture, distribution and provision of cannabis products to the adult-use, wellness and medical markets in Canada.

This vertically integrated cannabis firm has its headquarters in Vancouver, Canada and was found-ed in 1987 on August 24 by Hugo M. Alves. Prior to its name change in June 2018, the firm was known as Cannabis Wheaton Income Corp. It operates as part of the freight forwarding services industry in the consumer staples sector, under the tobacco and cannabis sub-industry. The firm serves consumers across the globe.

The company operates through the South American cannabis operations, Research operations and Canadian cannabis operations segments. While the South American segment is involved in the cul-tivation of marijuana products through Inverell SA, the research operations segment provides re-search services for consumers who are carrying out clinical trials. On the other hand, the Canadian operations segment is made up of the growing and sale of cannabis 2.0 and other cannabis prod-ucts in Canada.

The enterprise provides products like oil drops, cannabis oil spray, chocolates, pre-rolled cannabis, vape pens, vape cartridges and soft chews under the Dosecan, Foray and Kolab Project brand names. It is also focused on supporting and investing in companies that cultivate cannabis.

The firm offers financial solutions to their partners for building and expanding, while allowing them to focus on innovation. This model enables their partners to achieve greater success, surpass their growth potential and enable partners to get to the market quicker. Additionally, their focus on expanding their product offerings allows the firm to build long-term stakeholder value, which en-courages more investments into the firm.

Auxly Cannabis Group (CBWTF), closed Monday's trading session at $0.06, up 21.7039%, on 1,842,531 volume. The average volume for the last 3 months is 6,556,795 and the stock's 52-week low/high is $0.0104/$0.06.

American Resources (AREC)

RedChip, QualityStocks, TradersPro, InvestorPlace, Zacks, MarketClub Analysis, MarketBeat, StreetInsider, StockMarketWatch, PoliticsAndMyPortfolio, InvestorsUnderground and BUYINS.NET reported earlier on American Resources (AREC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

American Resources Corporation (NASDAQ: AREC) is focused on supplying raw materials to the infrastructure market.

The firm has its headquarters in Fishers, Indiana and was incorporated in 2006. It is focused on extracting, processing, transporting, distributing and selling metallurgical coal and PCI (pulverized coal injection) to the steel industry. It serves consumers across the globe.

The company has a growing portfolio of operations found in south Western Virginia and Eastern Kentucky’s central Appalachian basin where metallurgical carbon deposits are located. It is focused on the operation of coal mine complexes, which are found mainly in the Letcher, Knott and Pike counties as well as in West Virginia, Wyoming County and Kentucky. The company’s main source of revenue is generated from the sale of coal and metallurgical coal utilized in pulverized coal in-jection.

Its mining operations include Wyoming county coal, Gold star mine, Knott county coal, Deane mining and McCoy Elkhorn coal. The Elkhorn mine is involved in mining and selling metallurgi-cal carbon while the Deane mine is involved in the production and sale of pulverized coal injection products, which are used in the steel industry. Additionally, the Knott mine also sells industrial products and PCI to the infrastructure industry while the Gold star mine comprises of a box-cut underground mine.

American Resources (AREC), closed Monday's trading session at $0.643, up 12.807%, on 15,208,047 volume. The average volume for the last 3 months is 659,125 and the stock's 52-week low/high is $0.41/$1.78.

Immix Biopharma (IMMX)

QualityStocks, MarketBeat, Make Penny Stocks Great Again, TradersPro, Broad Street, Epic Stock Picks, Wolf of Penny Stocks, 360wallstreet, AwesomeStocks, BioMedWire, Buzz Stocks, Fierce Analyst, HotOTC, InsiderTrades, 247 Market News, Jeff Bishop, MarketClub Analysis, Penny Pick Finders, Small Cap Firm, StockOnion, StockStreetWire, StockWireNews and InvestorsUnderground reported earlier on Immix Biopharma (IMMX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Immix Biopharma Inc. (NASDAQ: IMMX) is a clinical-stage biopharmaceutical firm that is fo-cused on the development of different tissue-specific therapeutics in inflammation and oncology.

The firm has its headquarters in Los Angeles, California and was incorporated in 2012. The firm serves consumers around the globe, with a focus on Australia and the United States.

The company is party to a clinical supply and collaboration agreement with BeiGene Ltd, which entails carrying out a phase 1b clinical trial in solid tumors of Tislelizumab and IMX-110. It de-velops a new class of tissue-specific therapeutics for patients with inflammatory diseases or can-cer, using the SMARxT Tissue-specific platform, which creates therapies that gather at intended therapeutic sites at five times the rate of current medications.

The enterprise’s product pipeline comprises of a tissue-specific biologic dubbed IMX-120, which has been developed to treat severe Crohn’s disease and ulcerative colitis; a tissue-specific biologic known as IMX-111, which is indicated for the treatment of colorectal cancers; and a combination therapy dubbed IMX-110, which is undergoing phase 1b/2a clinical trials evaluating its effective-ness in treating solid tumors and soft tissue sarcoma. IMX-110 has been designed to inhibit evolvability of cancer and cancer resistance while inducing apoptosis.

Immix Biopharma (IMMX), closed Monday's trading session at $1.78, up 12.6582%, on 113,106 volume. The average volume for the last 3 months is 95,860 and the stock's 52-week low/high is $1.26/$3.74.

ICL Group (ICL)

The Online Investor, MarketBeat, DividendStocks, Zacks, MarketClub Analysis, InvestorPlace, FreeRealTime, The Wealth Report, Marketbeat.com, TradersPro, StreetInsider, QualityStocks and Daily Stocks reported earlier on ICL Group (ICL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ICL Group Limited (NYSE: ICL) (TLV: ICL) is a specialty minerals and chemicals company fo-cused on manufacturing mineral-based products for the agriculture, food, and engineered materi-als markets.

The firm has its headquarters in Tel Aviv, Israel and was incorporated in 1968. Prior to its name change in May 2020, the firm was known as Israel Chemicals Limited. It operates as part of the agricultural inputs industry, under the basic materials sector. The firm serves consumers around the globe.

ICL Group operates through the Growing Solutions, Industrial Products, and Phosphate Solu-tions segments. The Growing Solutions segment develops, manufactures, markets, and sells ferti-lizers based primarily on nitrogen, potash, and phosphate, including water soluble specialty, liq-uid, soluble, and controlled-release fertilizers. The Phosphate segment mines and produces potash and salt; extracts potash from the Dead Sea; produces, markets, and sells magnesium and magne-sium alloys, as well as related by-products, including chlorine and sylvinite; produces polysulfate; and sells salt. This segment uses phosphate commodity products to produce specialty products; produces and markets phosphate-based fertilizers, as well as sulfuric acid, green phosphoric acid, and phosphate fertilizers; and provides Phosphate salts and acids for various industrial end mar-kets, such as oral care, cleaning products, paints and coatings, water treatment, asphalt modifica-tion, construction, and metal treatment. In addition to this, it develops and produces functional food ingredients and phosphate additives for use in the processed meat, poultry, seafood, dairy, beverage, and baked goods markets; and produces milk and whey proteins for the food ingredi-ents industry. The Industrial Products segment produces various grades of potash, salt, magnesi-um chloride, and magnesia products; produces bromine out of a solution that is a by-product of the potash production process, as well as bromine-based compounds; and produces and markets phosphorous-based flame retardants and other phosphorus-based products. The enterprise sells its products through marketing companies, agents, and distributors.

ICL Group (ICL), closed Monday's trading session at $6.03, off by 1.9512%, on 910,668 volume. The average volume for the last 3 months is 12,351,720 and the stock's 52-week low/high is $3.79/$6.565.

Coinbase Global Inc. (COIN)

Schaeffer's, QualityStocks, InvestorPlace, Zacks, MarketClub Analysis, The Street, StockEarnings, Prfmonline, MarketBeat, Early Bird, Greenbackers, Kiplinger Today, INO Market Report, Investopedia, The Online Investor, OTCPicks, SmallCapVoice, Ceocast News, The Wealth Report, InsiderTrades, HotOTC, CoolPennyStocks, Daily Trade Alert, StocksEarning, Trades Of The Day, StockEgg, FreeRealTime, Penny Invest, Jeff Bishop, TradersPro, Stock Stars, CryptoCurrencyWire, Eagle Financial Publications, Stock Rich, Top Pros' Top Picks, Investors Underground, The Stock Psycho, Top Gun, CNBC Breaking News, BestOtc, Wealth Daily, Cabot Wealth, BullRally, HotShotStocks, BillionDollarClub, StockHotTips, PennyTrader Publisher, DividendStocks, Energy and Capital, FeedBlitz, Profit Confidential, Smartmoneytrading, Louis Navellier, Today's Financial News, bullseyeoptiontrading, MarketClub Options, Stockpalooza, PennyInvest, MadPennyStocks, Summa Money, StockRich, PennyStockVille, AllPennyStocks, Dawn Report, wealthmintrplus, Blaque Capital Stocks, BloomMoney, Stock Analyzer, wyatt research newsletter, WiseAlerts, AlphaShark Trading, Atomic Trades, Dynamic Wealth Report, CRWEWallStreet, Stock Fortune Teller, Premium Stock Alerts, Pennybuster, Penny Stock Rumble, StockMister, Momentum Traders, MicrocapVoice, TipRanks, TradingPub, Round Up the Bulls, Standout Stocks, Penny Stock Finder, Stock Traders Chat, Trading with Larry Benedict, Green Chip Stocks, Earnings360, Early Investing, Wealth Whisperer and InvestorsUnderground reported earlier on Coinbase Global Inc. (COIN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The cryptocurrency market experienced a sharp decline on Monday, erasing over $110bn in value as Bitcoin (BTC) and altcoins dropped to their lowest levels in weeks. This sudden downturn followed a period of stability and was driven by growing economic concerns and unsettling developments within the crypto asset sector.

Leveraged positions lost $882 million as a result of the sell-off, making it one of the biggest liquidations in recent weeks. Over 284,000 crypto traders were forced to exit their trades, with those holding long positions suffering the most severe losses.

Bitcoin’s value plummeted from $96,954 to a monthly low of $90,924, leading to long liquidations amounting to $256 million before staging a partial recovery. Ether also had a steep decline, plunging to $2461—a more than 10% decline—wiping out $176 million in long positions.

The biggest percentage decline occurred in Solana, which fell 13% to $136, resulting in long liquidations of $83 million and short-position liquidations of $8 million.

Cardano’s CEO, Charles Hoskinson, voiced his frustration over investor reactions, suggesting that many had lost sight of the bigger picture. He compared the market’s behavior to that of a child throwing a tantrum, criticizing the panic-driven sell-off.

The market’s volatility comes as President Donald Trump reinstates 25% tariffs on imports from Canada and Mexico. Earlier optimism had stemmed from a temporary suspension of these trade barriers, but their return has reignited concerns about economic stability.

Investor confidence has also been shaken by the scandal involving insider trading of Solana-based meme coins. The controversy led to substantial fund withdrawals from Solana, heightening anxiety across the broader market.

At the same time, Ether and Bitcoin ETFs have seen heavy outflows, further pressuring prices. Data from SoSoValue indicates that Ether ETFs saw $85.3 million in withdrawals over the last two weeks, while BTC ETFs saw the largest exit since its introduction of $1.14 billion.

Moreover, the market is still grappling with the impact of a recent $1.5 billion cyberattack on the Bybit exchange, making selling pressure worse as traders scramble to secure their assets.

The crypto greed and fear index, which has fallen to 27, solidly in the “fear” range, indicates that worry has taken hold. A month earlier, the measure stood at 61, indicating a strong degree of optimism. A reading below 41 implies that market activity is dominated by widespread anxiety, whereas a reading over 41 often denotes positive or neutral sentiment.

Major crypto exchanges like Coinbase Global Inc. (NASDAQ: COIN) are likely to watch the trading activity on their platforms to see if the market sentiment changes soon from the current sell-off to a more bullish stance.

Coinbase Global Inc. (COIN), closed Monday's trading session at $215.62, up 3.4794%, on 9,031,205 volume. The average volume for the last 3 months is 212,143,639 and the stock's 52-week low/high is $3.38/$7.76.

Canaan Inc. (CAN)

QualityStocks, MarketClub Analysis, Schaeffer's, StockEarnings, InvestorPlace, TradersPro, MarketBeat, CryptoCurrencyWire, AllPennyStocks, StreetInsider, Stockhouse, Dividend Report, Energy and Capital, INO Market Report, Investment Insights Report, Investors Alley, Acorn Wealth, Wealth Daily, The Online Investor, InvestorsUnderground, SmarTrend Newsletters, Stock Fortune Teller, StockMarketWatch, StocksEarning, Early Bird, The Street, BUYINS.NET, TopStockAnalysts and Trades Of The Day reported earlier on Canaan Inc. (CAN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The millions of dollars that Big Tech and cryptocurrency firms used to support Donald Trump’s re-election campaign are now yielding substantial returns. Ever since he took office, the government led by Trump has rolled out a series of tech-friendly directives, among them being deregulation, lawsuit dismissals, and policy rollbacks that benefit major industry players.

The current administration has adopted a hands-off regulatory approach, reversing many policies that previously sought to hold tech giants accountable. Among the biggest beneficiaries of these moves are artificial intelligence (AI), cryptocurrency, and social media firms, many of which contributed significantly to Trump’s campaign. The shift marks a stark contrast to the more adversarial stance taken by the previous administration, particularly in areas like AI regulation and crypto oversight.

One of the most notable beneficiaries of Trump’s policy changes is Elon Musk, the billionaire CEO of Tesla, SpaceX, and other tech ventures. Having donated nearly $300 million to Trump’s campaign, Musk now leads the Department of Government Efficiency (Doge), a new agency focused on reducing federal spending and eliminating regulations. Under Trump’s authority, legal actions against Musk’s companies, including SpaceX, have been dropped, signaling a clear reward for his financial and political support.

The cryptocurrency sector, which has long faced regulatory scrutiny, is now seeing a friendlier environment under Trump. A major example is the Securities and Exchange Commission (SEC) dropping its lawsuit against Coinbase, a leading crypto exchange, just weeks after the company donated $1 million to Trump’s inaugural fund. Additionally, Trump has appointed a pro-crypto SEC commissioner, signaling further industry-friendly policies ahead.

The crypto market has responded favorably, with many digital assets experiencing price surges following Trump’s re-election. His administration’s stance aligns with his campaign promise to be the “crypto president,” further cementing the industry’s backing.

Trump’s administration has also moved aggressively to dismantle AI safety regulations introduced under the Biden administration. A key executive order has rescinded policies that required AI companies to meet strict safety and transparency standards. As a result, the AI Safety Institute, responsible for overseeing ethical AI development, faces mass layoffs, raising concerns about unchecked AI advancements.

Many tech leaders who previously distanced themselves from Trump are now aligning with him, including Apple’s Tim Cook, Amazon’s Jeff Bezos, Meta’s Mark Zuckerberg, and OpenAI’s Sam Altman. These executives have contributed millions to Trump’s political efforts and have attended closed-door meetings with the president, highlighting their evolving relationship.

While the administration’s moves favor Big Tech and crypto, regulatory threats remain. The Federal Trade Commission (FTC) has announced an inquiry into “big tech censorship,” warning companies against policies that could be seen as politically biased. This suggests that while Trump is supporting tech interests, he expects loyalty in return.

With Trump’s policies reshaping the regulatory landscape, the tech industry appears poised for significant gains—proving that, in Washington, political investments can deliver lucrative returns. It remains to be seen how the growth trajectory of entities like Canaan Inc. (NASDAQ: CAN) will be boosted by the improving regulatory climate in the U.S.

Canaan Inc. (CAN), closed Monday's trading session at $1.31, up 2.3438%, on 10,436,775 volume. The average volume for the last 3 months is 10,491,448 and the stock's 52-week low/high is $0.72/$3.27.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO)

Green Car Stocks, QualityStocks, InvestorPlace, StocksEarning, Kiplinger Today, Schaeffer's, MarketClub Analysis, StockMarketWatch, GreenCarStocks, TradersPro, StockEarnings, BUYINS.NET, Trades Of The Day, MarketBeat, The Street, TopPennyStockMovers, Zacks, Daily Trade Alert, The Online Investor, Small Cap Firm, SmallCapVoice, VectorVest, Eagle Financial Publications, Cabot Wealth and PoliticsAndMyPortfolio reported earlier on ElectraMeccanica Vehicles Corp. Ltd. (SOLO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Combating battery electric vehicle (BEV) fires poses several new challenges for firefighters due to the energy-dense battery packs that power electric cars. EV fires burn much hotter than regular fires and require several times more water to put out, making them a harrowing experience for any firefighter who has come face to face with a combusting electric car.

Internal combustion engine (ICE) vehicle fires are already quite destructive. Still, an EV fire has the potential to cause significantly more property damage as it is a lot harder to put out. On average, an EV fire burns at a whopping 5,000 degrees Fahrenheit while an ICE fire burns at around 1,500 degrees. Additionally, an electric car fire requires 25,000 to over 100,000 gallons of water to put out compared to just 500 to 1,000 for an ICE vehicle fire, making them incredibly challenging to deal with.

Since conventional firefighting strategies are ineffective against electric vehicle fires, the average firefighter is extremely unprepared to respond to an EV fire, especially if it is located in urban regions where the fire can spread to infrastructure and other cars.

EV battery packs are largely to blame for the intensity of EV fires. The average EV battery pack contains hundreds to thousands of individual lithium-ion battery cells housed in a robust protective shell. Once a battery pack catches fire, throwing water on it isn’t enough to put it out as the protective shell encasing the batteries acts as a barrier against the water.

Firefighters in Chesterfield County recently faced the terror of a difficult-to-extinguish electric vehicle fire and spent an intense three hours working to put the flames out. Their efforts were ultimately successful, but the ordeal underscored just how complex fighting EV fires is. To equip their staff with the skills they need to combat EV fires now and in the future, several firefighting departments across the country have been providing intensive specialized training since 2020.

This training works to improve the patience and precision, skills that are critical to putting out EV fires. As the Chesterfield County fire showed, fighting an EV fire is a time-consuming and complex process that can take several hours to complete. Battalion Chief Rich Grassel says that in some cases, letting the fire naturally burn itself out is the most eco-friendly way of dealing with EV fires. However, this strategy’s deployment is dependent on key factors like where the fire is located and whether there is any potential fuel within the fire’s vicinity.

Virginia has already mandated statewide electric vehicle fire training and states like California, which are home to a large portion of the country’s EV fleet are likely to require such training in the near future. The Chesterfield County Firefighting Battalion is among the groups that have received specialized EV fire training emphasizing patience and precision.

Players in the EV space, such as ElectraMeccanica Vehicles Corp. Ltd. (NASDAQ: SOLO), need to work towards coming up with ways to modify battery chemistries so that any fire that breaks out is easier to contain and doesn’t cause extensive damage.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO), closed Monday's trading session at $0.2122, even for the day. The average volume for the last 3 months is 175,562 and the stock's 52-week low/high is $0.7104/$2.8.

TerrAscend Corp. (TSNDF)

QualityStocks, CannabisNewsWire, InvestorPlace and Cabot Wealth reported earlier on TerrAscend Corp. (TSNDF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A barely-known IRS credit scheme has allowed a multi-state marijuana operator (MSO) to earn millions of dollars in tax credits. Although cannabis firms remit hundreds of millions of dollars in taxes annually, federal law prevents them from claiming tax credits and deductions for operational expenses. However, Jushi Holdings took advantage of an obscure tax credit scheme to earn a little over $5 million.

The Boca Raton-based vertically integrated MSO was owed around $6 million worth of Employee Retention Credit (ERC) by the IRS but would have had to wait for several months to claim the credit. Rather than buckle down and wait, the cannabis operator sold the ERC claims to another party for $5.1 million in cash. ERC is a refundable tax credit for tax-exempt organizations and eligible businesses whose staff was impacted by the coronavirus pandemic.

Few cannabis firms have attempted to determine their eligibility for the tax credit in the years since the pandemic. Frost notes that while marijuana operators can still reap through the tax credit, they are running out of time. These firms have until April 15 to submit ERC claims for the 2021 tax year. Like Jushi, eligible companies that don’t want to wait for the IRS to pay out ERC claims can also sell their claims to third parties.

According to Jushi chief strategy officer Trent Woloveck, this is similar to invoice factoring where firms can sell pending invoices to third parties for cash. Woloveck explains that the IRS has taken its time delivering the ERC refunds to eligible companies in various industries, hence the decision to sell its claim to a third party.

Although the cash Jushi received was almost $1 million less than the value of its claim, Woloveck says it boosted the firm’s liquidity in its balance sheet. The IRS has already sent Jushi a $1.3 million check for previously filed claims and owes the multi-state operator $3 million in outstanding ERC claims. Woloveck says the firm expects the IRS to pay the remaining ERC claims ‘in due course.’

The Employee Retention Credit was included in the Coronavirus Aid, Relief and Economic Security (CARES) to incentivize businesses to retain their employees through the pandemic. Holland & Hart marijuana industry-focused lawyer Rachel Gillette notes that the IRS paid out the credits at a fast rate in the beginning but can now take up to 24 months to issue the credits to eligible companies.

It would be interesting to hear what other U.S. cannabis firms like TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) think about the program that Jushi has leveraged to get millions from the IRS in tax credits.

TerrAscend Corp. (TSNDF), closed Monday's trading session at $0.5, off by 1.3729%, on 396,709 volume. The average volume for the last 3 months is 322,930 and the stock's 52-week low/high is $0.49/$2.2.

Green Thumb Industries Inc. (GTBIF)

QualityStocks, InvestorPlace, MarketBeat, CannabisNewsWire, Wealth Insider Alert, Cabot Wealth, Trades Of The Day, TradersPro, Daily Trade Alert, The Street, The Online Investor, CFN Media Group, StreetInsider, Zacks, Top Pros' Top Picks, Trading For Keeps, wyatt research newsletter, Prism MarketView, Kiplinger Today, Daily Profit and Technology Profits Daily reported earlier on Green Thumb Industries Inc. (GTBIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

In spite of the widespread use of cannabis, businesses in the industry have faced significant challenges. Despite the continued growth in retail sales, many brands find it challenging to differentiate themselves in a market that largely views cannabis as a commodity. Even some of the biggest players have filed for bankruptcy due to these difficulties.

A prime example is Planet 13, a well-known cannabis retailer in Las Vegas that features a massive retail space, a restaurant, and a consumption lounge. However, despite its success in Nevada, the company has had trouble replicating that achievement in other locations. No cannabis brand has achieved dominance; rather, most brands resemble generic stores.

One of the key obstacles is pricing. Consumers, who are typically well-informed about cannabis, prioritize the product’s quality—such as its strain and THC content—over brand names. As a result, companies find it difficult to charge premium prices when buyers perceive little difference between brands. Celebrity-backed products, such as those from Tommy Chong or Mike Tyson, often fare better because they leverage name recognition rather than relying on a standalone brand identity.

While demand for marijuana remains strong, brands still face the challenge of convincing consumers to choose them over competitors. This struggle for differentiation has been a major factor in Bright Green Corporation’s recent financial troubles, which recently filed for bankruptcy.

Bright Green Corporation, founded in 2019 and based in New Mexico, specializes in the production of legal marijuana and marijuana extracts. The company operates in manufacturing, research, and medical marijuana production.

Unlike most other cannabis businesses that have gone bankrupt, Bright Green Corporation has found a way forward. The company has reached a Restructuring Support Agreement (RSA) with Lynn Stockwell, a key shareholder, to facilitate a reorganization. Under this agreement, Stockwell will take over as CEO upon court approval. The restructuring plan includes a 1-for-50 reverse stock split and provisions for unsecured creditors to receive a mix of equity and cash.

Stockwell, who also founded Drugs Made in US Acquisition Corp I and II, aims to bring pharmaceutical ingredient manufacturing back to the U.S.

The company is the first publicly traded company in the U.S. to have direct involvement with marijuana cultivation. It plans to collaborate with the HHS to support cannabis research at its New Mexico facility. Additionally, it is exploring a franchise model to expand its agricultural operations in Central New Mexico, East Arizona, and West Texas.

As the marijuana industry matures in different jurisdictions, mergers and acquisitions, bankruptcies and other hallmarks of market consolidation are bound to become increasingly common. It is now up to leading brands like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) to study the evolving market and position themselves appropriately to benefit from these shifts.

Green Thumb Industries Inc. (GTBIF), closed Monday's trading session at $6.95, off by 3.4722%, on 392,632 volume. The average volume for the last 3 months is 1,179,957 and the stock's 52-week low/high is $6.6/$16.33.

NEWTON GOLF (SPGC)

The Online Investor, QualityStocks and Premium Stock Alerts reported earlier on NEWTON GOLF (SPGC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NEWTON GOLF (NASDAQ: SPGC) , a Sacks Parente company, is a technology-forward golf equipment manufacturer committed to enhancing player performance through innovative design. “NEWTON GOLF is focused on delivering high-performance golf equipment with a strong emphasis on precision engineering and cutting-edge materials,” reads a recent article. “The global golf equipment market was valued at approximately $8 billion in 2022, with the U.S. market accounting for $2.9 billion. The golf club segment dominated the industry, representing 45.7% of total market share. Increasing participation in golf, particularly among younger players and women, is driving demand for high-quality, customizable golf equipment.”

To view the full article, visit https://ibn.fm/LpezT

About NEWTON GOLF Company

NEWTON GOLF: A Sacks Parente company, is a technology-forward golf company that help golfers elevate their game. With a growing portfolio of golf products, including putters, golf shafts, golf grips, and other golf-related accessories, the company’s innovative accomplishments include: the First Vernier Acuity putter, patented Ultra-Low Balance Point (“ULBP”) putter technology, weight-forward Center-of-Gravity (“CG”) design, and pioneering ultra-light carbon fiber putter shafts.

In consideration of its growth opportunities in golf shaft technologies, the company expanded its manufacturing business in April of 2022 to develop the advanced Newton brand of premium golf shafts by opening a new shaft manufacturing facility in St. Joseph, Missouri. It is the company’s intent to manufacture and assemble substantially all products in the United States, while also expanding into golf apparel and other golf-related product lines to enhance its growth.

The company’s future expansions may include broadening its offerings through mergers, acquisitions or internal developments of product lines that are complementary to its premium brand. The company currently sells its products through resellers, the company’s websites, Club Champion retail stores, and distributors in the United States, Japan, and South Korea.

For more information, visit the company’s website at www.newtongolfco.com .

NEWTON GOLF (SPGC), closed Monday's trading session at $0.2086, off by 48.6207%, on 58,214,109 volume. The average volume for the last 3 months is 309,999 and the stock's 52-week low/high is $0.2002/$6.913.

The QualityStocks Company Corner

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene is partnering with APST Research GmbH to analyze neurofilament light chain ("NfL") data for evaluating CNM-Au8 ® in ALS patients.

APST maintains one of the largest ALS biomarker databases, with data from over 4,300 ALS patients, including clinical outcomes and biomarker tracking.

The analysis will compare NfL changes in the NIH-sponsored Expanded Access Program ("EAP") participants with historical ALS patient data to assess CNM-Au8's potential efficacy.

Clene plans to submit its statistical analysis plan to the FDA, aiming for filing of an NDA for potential accelerated approval in the second half of 2025.

No significant safety concerns have been reported across over 800 participant years of CNM-Au8 treatment.

Clene Inc. (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis ("ALS") and multiple sclerosis ("MS"), has signed an agreement with APST Research GmbH ("APST") to support analyses of CNM-Au8's effects on NfL decline in participants in ongoing EAPs ( https://ibn.fm/2IwhG ). The analyses were recommended by the U.S. Food and Drug Administration ("FDA") to support Clene's data package for a potential accelerated approval application.

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Monday's trading session at $4.5, up 1.81%, on 31 volume. The average volume for the last 3 months is 46,720 and the stock's 52-week low/high is $3.8181/$10.4.

Recent News

Calidi Biotherapeutics Inc. (NYSE American: CLDI)

The QualityStocks Daily Newsletter would like to spotlight Calidi Biotherapeutics Inc. (NYSE American: CLDI).

Calidi Biotherapeutics (NYSE American: CLDI) and OS Therapies Inc. (NYSE American: OSTX) will be featured on RedChip's Small Stocks, Big Money show, airing on Bloomberg TV this Saturday, March 1, at 7 p.m. ET. Andrew Jackson, CFO of Calidi, will discuss the company's stem cell-based oncolytic virotherapy platform designed to enhance cancer treatment. Calidi's lead candidates, CLD-101 and CLD-201, target significant market opportunities estimated between $13 billion and $15 billion in the U.S. OS Therapies CEO Paul Romness will highlight OST-HER2, an immunotherapy targeting HER2-positive osteosarcoma and solid tumors, with potential for accelerated FDA approval. The company also advances a tunable ADC platform for precision cancer treatments.

To view the full press release, visit: https://ibn.fm/Q0awX

Calidi Biotherapeutics Inc. (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering proprietary technology that empowers the immune system to combat cancer. Calidi’s innovative, off-the-shelf cell-based platforms use allogeneic stem cells to deliver potent oncolytic viruses (OVs) across multiple oncology indications, including high-grade glioma (brain cancers) and solid tumors. In addition, Calidi has presented a breakthrough systemic technology, RTNova, which utilizes an exteracellular enveloped virotherapy. RTNova is pre-clinical and has been extremely well-received by market analysts and large-cap biopharma – opening the door for potential collaboration.

These cell-based platforms are engineered to protect, amplify, and enhance the efficacy of oncolytic viruses, resulting in improved patient safety and potentially advancing treatment outcomes for metastatic disease. By employing a dual approach that combines OV delivery with immune activation, Calidi’s therapies aim to not only treat but potentially prevent the spread of metastatic cancers.

The company’s development pipeline leverages this technology to address pressing needs in cancers such as glioblastoma (brain cancer), metastatic melanoma, triple-negative breast cancer, head & neck cancer, and lung cancer. Calidi’s approach has shown early signals of efficacy and safety, establishing it as a distinctive player in the growing OV market, which is projected to increase significantly in value over the next decade.

Calidi is headquartered in San Diego, California.

Products

Calidi’s product pipeline includes advanced cell-based platforms targeting a variety of oncology indications, each designed to harness the power of oncolytic virotherapy for improved cancer treatment outcomes.

  • NeuroNova (CLD-101): A platform designed for treating high-grade gliomas (HGG), NeuroNova employs neuronal stem cells combined with an engineered adenovirus (CRAD-s-Pk7) to selectively target glioma cells. After a successful Phase 1 safety study in newly diagnosed HGG, NeuroNova has now progressed into Phase 1/1b trials for recurrent cases. FDA clearance for a Phase 1b/2 trial at Northwestern University was received in September 2024, with patient enrollment expected to begin in Q1 2025. This trial will utilize multiple-dose intracerebral administration to maximize safety and efficacy in newly diagnosed HGG patients.
  • SuperNova (CLD-201): Built on Calidi’s foundational technology, SuperNova utilizes an engineered Vaccinia virus (CAL1) delivered via allogeneic adipose-derived mesenchymal stem cells to target advanced solid tumors, including head & neck, triple-negative breast cancer, and soft tissue sarcomas. Early studies with autologous stem cells demonstrated both safety and promising efficacy, and Calidi plans to begin a Phase 1 trial with multiple dose regimens for SuperNova in the coming months.
  • RTNova (CLD-400): Calidi’s systemic delivery platform for lung and metastatic cancers, RTNova employs an extracellular enveloped virotherapy (envRT-01) technology for intravenous (IV) administration, simplifying the treatment process and expanding its potential applications. Currently in preclinical stages, RTNova focuses on demonstrating efficacy and safety through systemic administration. A clinical trial targeting metastatic lung cancer is anticipated for Q2 2026, using a single-arm monotherapy with dose escalation. Calidi has partnered with SIGA Technologies (NASDAQ: SIGA) to support the development of this program.

Market Opportunity

The global oncology drugs market was valued at $201.75 billion in 2023 and is projected to grow to $518.25 billion by 2032, with a CAGR of 11.3%. The oncolytic virotherapy market in particular is growing rapidly, driven by increasing approval rates and significant unmet needs.

The market for OV treatments is expected to expand from one approved product generating $150 million in the U.S. in 2021 to 6-8 approved therapies generating $2.4 billion by 2030. As a leader in OV technology, Calidi is well-positioned to address these high-demand areas in oncology.

Alongside global trends, the American Cancer Society projects nearly two million new cancer diagnoses in the U.S. in 2024, reflecting a 28% increase since 2010. This underscores the urgent need for novel therapies that not only treat disease progression but also enhance patient quality of life, reinforcing the demand for Calidi’s innovative approaches.

Management Team

Allan Camaisa, CEO, Chairman, and co-founder, is a seasoned leader with extensive experience in scaling businesses to successful exits. Mr. Camaisa previously led High Technology Solutions, growing it from two employees to over 500 with $50 million in revenue. He also served as CEO of Parallel6 Inc. and is a U.S. Naval Academy graduate with further studies at Harvard Business School.

Antonio Santidrian, Ph.D., Chief Scientific Officer, leads all research and development initiatives at Calidi and is the coinventor of the company’s CLD-201 (Supernova) and CLD-400 (RTNova) platforms. Since joining Calidi in 2015, he has applied his 20+ years of expertise in academia and biotech, focusing on anti-cancer translational research, to drive the company’s innovative drug pipeline. Before Calidi, Dr. Santidrian led translational studies at The Scripps Research Institute, advancing treatments for breast cancer metastasis, and contributed to the development of ACADRA for chronic lymphocytic leukemia (CLL) at the University of Barcelona, Spain.

Boris Minev, M.D., President of Medical and Scientific Affairs, is a renowned physician-scientist with expertise in Immuno-Oncology, stem cell biology, and oncolytic viruses. Previously, Dr. Minev served as Director of Immunotherapy and Translational Oncology at Genelux Corporation and remains an adjunct professor at the Moores UCSD Cancer Center. His background includes research at the National Cancer Institute.

Andrew Jackson, CFO, has held executive finance roles with experience in biotech and clinical-stage companies, including Eterna Therapeutics and Ra Medical Systems. Mr. Jackson holds an MSBA in Finance from San Diego State University and a BSB in Accounting from the University of Minnesota.

Calidi Biotherapeutics Inc. (NYSE American: CLDI), closed Monday's trading session at $0.8795, up 5.5569%, on 3,060 volume. The average volume for the last 3 months is 2,340,938 and the stock's 52-week low/high is $0.58/$8.3.

Recent News

FAVO Capital Inc. (OTC: FAVO)

The QualityStocks Daily Newsletter would like to spotlight FAVO Capital Inc. (NASDAQ: FAVO).

FAVO Capital (OTC: FAVO) integrates fintech-driven enhancements to improve funding speed and flexibility for underserved small and medium-sized businesses. "As traditional banks pull back from small business lending, the demand for alternative financing solutions has surged. FAVO Capital is stepping up to fill this void by developing cutting-edge fintech solutions that streamline the lending process and provide fast access to capital," reads a recent article discussing the company. "Headquartered in Fort Lauderdale, Florida, with a workforce of over 120 professionals across five global offices, FAVO is carving out a niche in the rapidly expanding private credit sector."

To view the full article, visit https://ibn.fm/U5bjz

FAVO Capital Inc. (OTC: FAVO) is redefining the private credit and alternative lending industry through a strategic redevelopment of its operations and offerings. With a focus on leveraging financial technology and a client-centric approach, FAVO Capital empowers small to medium-sized businesses with fast, flexible, and reliable access to capital, bridging the gap left by traditional financial institutions.

Empowering Businesses, Redefining Private Credit

As part of its strategy to uplist to Nasdaq, FAVO Capital is enhancing its technology platform, operational scalability, and market positioning to meet higher regulatory standards and attract institutional investors. Headquartered in Fort Lauderdale, Florida, FAVO employs over 120 professionals across five global offices, delivering sustainable growth and value for clients and shareholders alike.

Products and Services

  • Proprietary Lending Platform and Mobile App (In Development): FAVO Capital is in the early stages of developing an advanced digital platform designed to enhance client engagement and streamline funding processes. This platform will eventually allow businesses to apply for funding products, track progress, and manage repayment efficiencies. A complementary mobile app is also being planned to provide real-time insights and tailored recommendations, laying the groundwork for an improved borrower experience.
  • Fintech-Driven Lending Solutions: FAVO Capital is exploring proprietary and third-party technology tools, including advanced analytics and algorithms, to enhance decision-making speed and reliability in the lending process.
  • Flexible Financing Options: FAVO specializes in structuring customized capital solutions tailored to the diverse needs of small business owners, offering scalable and adaptable products that evolve with changing market conditions.

Market Opportunity

The private credit market is experiencing exponential growth as traditional banks reduce their focus on small business lending. According to industry reports, the global private credit market is projected to surpass $1.5 trillion by 2025, driven by increasing demand for alternative financing options.

FAVO Capital is uniquely positioned to capture market share within this booming sector by leveraging fintech innovation to meet the needs of underserved small businesses. With a focus on efficiency, speed, and client satisfaction, FAVO addresses critical gaps in the financial ecosystem while building a platform for long-term growth.

Recent Highlights

  • Fintech Innovation: Initial investments in app development and analytics lay the groundwork for future operational efficiency and improved borrower experience.
  • Operational Scale: A global footprint with over 120 employees combines the agility of a local lender with the reach of an international financial institution.
  • Proven Growth: FAVO’s technology-driven approach has enabled consistent expansion, solidifying its reputation as a trusted partner for small businesses.

Leadership Team

Vincent Napolitano is a Founder and CEO of FAVO Capital Inc. With over two decades of experience in finance and business development, Vincent has been instrumental in building FAVO Capital into a trusted partner for businesses seeking innovative financial strategies. Prior to founding FAVO Capital, Vincent spent 25 years on Wall Street, holding key positions at prominent firms and developing expertise in structuring complex financial deals. He also served as Chief Investment Officer for multiple special purpose vehicles (SPVs), acquiring private stock in pre-IPO unicorn companies such as Facebook and Twitter.

Shaun Quin is a Founding Member and President of FAVO Capital Inc., overseeing the company’s mission to deliver innovative and efficient private credit solutions to small and medium-sized businesses. With over 20 years of global experience as a partner, investor, and director, Shaun brings a strategic and customer-focused approach to his leadership. His expertise in fostering collaboration, building high-performance cultures, and empowering businesses has positioned FAVO Capital as a trusted leader in private lending.

Vaughan Korte, CFO, brings over 15 years of global financial expertise to his role with FAVO Capital Inc. His track record includes managing financial operations for Adidas across 60 countries with budgets exceeding $500 million. Vaughan’s leadership ensures FAVO Capital remains financially resilient, aligning financial strategy with organizational goals and fostering shareholder value.

Glen Steward, Chief Strategy Officer, is a seasoned entrepreneur with over 28 years of experience in the investment and trading industries. He drives FAVO Capital’s strategic initiatives, ensuring the company remains competitive and agile in a rapidly evolving market. Glen has held directorships and board memberships across Mauritius, South Africa, and the United States. His strategic acumen has been pivotal in integrating the FAVO Group of Companies into FAVO Capital Inc., fueling growth and market leadership.

Advisory Board

Bilal Adam, Accounting & Financial Counsel, is a financial expert with over 20 years of experience, including roles as CEO of Stewards Investment Capital. His insights into bespoke investment solutions, including fixed income, equity, and digital assets, support FAVO Capital’s innovative approach to private credit.

Honorable Earnest Hart, Corporate Governance Counsel, brings decades of legal and governance experience, having served as a New York Supreme Court Judge and COO at Columbia University Medical Center. His guidance ensures FAVO Capital maintains robust corporate governance standards.

Rocco Trotta, Business Leadership and Scalability Counsel, is the co-founder of LiRo-Hill and has decades of experience scaling businesses. His expertise in organizational efficiency and talent development strengthens FAVO Capital’s ability to attract excellence across all aspects of the business.

As FAVO Capital redevelops its operations and prepares for an uplisting to Nasdaq, the company is laying the foundation to redefine private credit with emerging fintech solutions and exceptional leadership. Learn more by visiting investors.favocap.com.

Investment Considerations
  • Early-Stage Technology Development: Laying the groundwork for proprietary platforms and scalable digital tools.
  • Significant Market Opportunity: The private credit market is projected to exceed $1.5 trillion by 2025, providing exponential growth potential.
  • Scalable Business Model: Automated processes and data-driven decision-making enable rapid scaling with minimal overhead.
  • Customer-Centric Approach: FAVO’s focus on small businesses and flexible financing solutions addresses critical gaps in the financial ecosystem.
  • Experienced Leadership: A forward-thinking executive team ensures strategic growth and innovation.

FAVO Capital Inc. (OTC: FAVO), closed Monday's trading session at $1, even for the day, on 3,013 volume. The average volume for the last 3 months is 3,290 and the stock's 52-week low/high is $0.162/$1.08.

Recent News

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF)

The QualityStocks Daily Newsletter would like to spotlightFathom Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF).

Aston Bay (TSX.V: BAY) (OTCQB: ATBHF) announced with deep sadness the passing of Dwight Walker, who served as Chief Financial Officer for the past nine years. Walker was a respected leader and integral member of the Aston Bay team, contributing significantly to the company's success with his extensive financial expertise and strategic vision. With over 30 years of experience, including a decade in the mining sector, he held CFO roles at multiple public companies throughout his distinguished career. CEO Thomas Ullrich expressed condolences, emphasizing Walker's invaluable contributions. The Board of Directors has appointed Donna McLean as interim CFO. McLean, currently Director of Accounting Services at Grove Corporate Service, brings 20 years of experience as CFO for public mining and exploration companies.

To view the full press release, visit https://ibn.fm/AScq1

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) is a publicly traded Canadian minerals exploration company focused on exploring high-grade copper and gold deposits in North America. The company owns the Storm Copper Project and the Seal Zinc Deposit in Nunavut, Canada, and is currently exploring the Buckingham Gold Vein and critical metals prospects in central Virginia. Aston Bay is also in the advanced stages of negotiation on other properties with high-grade critical minerals potential in these areas.

The company believes in responsible exploration and carries out its work programs to the highest standards of social responsibility, environmental stewardship and health and safety. Aston Bay cares about leaving a net positive impact on the communities in which it works and engages with local representatives, Indigenous groups and government agencies to build respectful relationships through dialogue and collaborative processes. Depending on the stage of exploration, these efforts may include employment, contracting, training, community benefits and other agreements.

Aston Bay conducts exploration through safe, socially and environmentally responsible and sustainable work practices. The company embeds core values of health and safety throughout its operations by adhering to strict health and safety standards and practices that meet and/or exceed industry standards and government codes and regulations.

The company is headquartered in Toronto.

Projects

Storm Copper

The high-grade Storm Copper Deposit is located 112 kilometers south of the community of Resolute Bay, Nunavut, on western Somerset Island, just south of the past-producing Polaris Pb-Zn Mine. The property comprises 173 contiguous mining claims, including the Storm Copper and Seal Zinc projects, covering an area of approximately 541,795 acres.

The property has good access to established shipping lanes, and the landscape provides favorable conditions for development of roads and a protected deep-water port. Exploration is supported through excellent infrastructure in the nearby hamlet of Resolute Bay.

Aston Bay is partnered with American West Metals (ASX: AW1) at Storm. American West is responsible for all exploration expenditures, having aggressively advanced the project toward production and earned an 80% interest. This affords excellent optionality to the company’s shareholders, as Aston Bay is free carried with no required expenditures until the completion of a bankable feasibility study.

American West recently completed an Australian JORC-compliant Maiden Resource Estimate for Storm; the North American 43-101 compliant resource estimate is expected in Q1 2024. American West is cashed up and plans a multimillion-dollar resource expansion and new discovery drilling program for the summer of 2024.

The Buckingham County Gold Project

The gold-bearing system at the Buckingham County Gold Project in Virginia lies within a belt hosting past producing mines, current gold mines and advanced gold explorations, stretching through Georgia, the Carolinas, Virginia, Nova Scotia and Newfoundland.

Buckingham hosts a “Kirkland Lake-style” high grade gold vein returning values consistently over one ounce gold per ton and is underexplored both at depth and along almost one mile of strike length. These types of veins have excellent ESG qualities, as they are typically mined using a small footprint underground method, with gold extracted using simple and environmentally friendly gravity methods.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

A report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Thomas Ullrich is CEO and Director of Aston Bay. He has over 30 years of experience in mineral exploration and geoscience. Before joining Aston Bay, he was Chief Geologist North America for Antofagasta Minerals plc, investigating copper potential through extensive property evaluations and management of drill programs in the United States, Mexico and Canada. Prior to that, he was Senior Geologist for Almaden Minerals.

Sofia Harquail handles Investor Relations and Corporate Development at Aston Bay. She has over 15 years of experience in the private and public sectors of the mining industry. Before joining Aston Bay, she worked as a consultant for the Prospectors and Developers Association of Canada and for exempt market dealer Red Cloud Financial Services Inc. Ms. Harquail holds an M.A. from the University of Uppsala in Sweden and received her CPIR designation from the CIRI/Ivey Investor Relations Program. She also sits on the board of the Young Mining Professionals Toronto and is CSC Certified.

Aston Bay has a talented Board of Directors bringing broad experience from across the industry, encompassing resource expansion, mine development, mergers and acquisitions, and mining finance.

Ms. Jessie Liu-Ernsting has over 15 years of experience in the mining industry, spanning capital projects engineering, debt capital markets, private equity and corporate strategy at several firms, including Hudbay Minerals and Resource Capital Funds. She is currently VP Investor Relations and Communications at G Mining Ventures Corp.

Mr. Jeffrey R. Wilson has over 25 years’ experience in the mining industry, having served as a director, officer and advisor of multiple public and private companies in the mineral exploration and mining investment industries. Mr. Wilson is currently President & CEO of Precipitate Gold Corp.

Mr. Gary O’Connor has over 40 years of diverse experience as a mineral exploration and development professional in the management of successful resource projects as well as the evaluation, technical due diligence, and supervision of large mineral exploration and development projects through-out the world. While with Freeport, Mr. O’Connor worked on the due diligence and discovery of a major gold fraud on the Busang gold “deposit” in Kalimantan by Bre-X.

Mr. Mark J. Pryor is a geologist with a 40-year track record of successfully advancing multiple precious metal, copper, coal, REE and Li projects from discovery through to exploitation. He is currently Executive Vice President of the Exploration Division at The Electrum Group.

Aston Bay Holdings Ltd. (OTCQB: ATBHF), closed Monday's trading session at $0.0368, even for the day, on 54,990 volume. The average volume for the last 3 months is 110,060 and the stock's 52-week low/high is $0.031/$0.1164.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

Forschungszentrum Jülich scientists have already leveraged D-Wave's technology for research on protein folding, electron interactions and quantum physics.

The Advantagesystem features over 5,000 qubits and 15-way connectivity, advancing quantum optimization research.

The quantum system will be linked to JUPITER, Europe's first exascale supercomputer, potentially enabling novel computational applications.

The system will be upgraded to D-Wave's next-generation Advantage2quantum processor when available, which D-Wave expects will deliver doubled coherence time, higher qubit connectivity and 40% improvement in energy scaling.

The collaboration is anticipated to take the use of quantum technology to a new level, according to Prof. Kristel Michielsen, head of JUNIQ & Quantum Computing at the Jülich Supercomputing Centre.

D-Wave Quantum Inc. (NYSE: QBTS) ("D-Wave"), a leader in quantum computing systems, software, and services, and the first supplier of production-grade quantum computers, recently announced that the Jülich Supercomputing Centre ("JSC") at Forschungszentrum Jülich ("FZJ") has become the world's first high-performance computing ("HPC") center to purchase a D-Wave TM Advantage annealing quantum computing system ( https://ibn.fm/KGsAg ).

AI has greatly enhanced the ability to predict the emergence and spread of diseases. A recent study highlights that continued advancements in this field rely on transparent data and lower training costs. AI has already been applied in various areas of healthcare, such as diagnosing patients, assisting doctors in decision-making, and predicting individual disease risks. However, its role in epidemiology remains limited, largely due to difficulties accessing large, standardized datasets required for effectively training AI models. Even though more data is now available than before COVID-19, many researchers are still unable to obtain regular surveillance data, which impedes progress in disease modeling. AI adoption has also been hampered by high computational costs. Improving AI-driven epidemiology research will need addressing these issues through cost-effective model training and ethical data sharing. Quantum computing systems from various companies like D-Wave Quantum Inc. (NYSE: QBTS) are likely to accelerate this process.

D-Wave Quantum Inc. (NYSE: QBTS) ("D-Wave") announced it will release its fourth quarter and fiscal year 2024 financial results on March 13, 2025, before market open. The company will host a conference call at 8:00 a.m. ET to discuss the results and business outlook, featuring CEO Dr. Alan Baratz and CFO John Markovich. Investors can access the press release on D-Wave's Investor Relations website. To view the full press release, visit https://ibn.fm/wr9fe

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Monday's trading session at $5.48, off by 1.4388%, on 862,068 volume. The average volume for the last 3 months is 65,281,399 and the stock's 52-week low/high is $0.7505/$11.41.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Two sources have revealed that BP is ditching plans to increase renewable energy generation capacity and refocusing its efforts on fossil fuels. The sources told Reuters that the chief executive is set to scrap the company's plan to boost green energy generation by 20 times through the rest of the decade, dealing a major blow to the clean energy industry's growth. The decision to ditch green energy is reportedly part of a shift in strategy to help BP assuage rising investor concerns about the firm's earnings. BP shares have struggled to compete with industry rivals for the past couple of years and fell by nearly 16% in 2024 compared to other major players in the oil sector. Furthermore, the firm recently scrapped its target of cutting gas and oil output by the end of the decade. BP may be abandoning its efforts to increase renewable energy generation to be more in line with U.S. policy as led by President Trump. The Republican is a staunch critic of green energy who has consistently batted for the fossil fuel industry. As a result, the U.S. is swiftly moving away from green energy and may not be in a position to buy renewable energy from energy companies in allied nations like the UK. While oil and gas firms like BP are ditching their plans to ramp up renewable energy production, entities like Mullen Automotive Inc. (NASDAQ: MULN) are making solid strides in their bids to address the market for zero-emission vehicles. Recent stock market movements for these firms show that investors strongly believe in the utility of these BEVs.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Monday's trading session at $2.57, off by 13.1757%, on 87,287 volume. The average volume for the last 3 months is 4,522,730 and the stock's 52-week low/high is $2.29/$47100.

Recent News

Torr Metals Inc. (TSX.V: TMET)

The QualityStocks Daily Newsletter would like to spotlightFathom Torr Metals Inc. (TSX.V: TMET) .

Torr Metals Inc. (TSX.V: TMET) is strategically advancing its Kolos Project near some of the most established and productive porphyry copper mines in Canada. "By developing the Kolos Project in southern British Columbia, near the Highland Valley, New Afton and Copper Mountain mines, Torr has positioned itself to fill the growing demand for copper as these nearby mines face declining ore reserves. To that point, Kolos stands poised to be part of the next generation of potentially new copper discoveries, providing much needed supply in one of the most prolific mining districts in the world," reads a recent article. "Torr's Kolos Project offers a timely and strategic potential solution to the pending copper supply gap in southern British Columbia, representing a significant opportunity to help sustain copper production in the region. Torr has already outlined two key, undrilled cluster porphyry systems at Kolos: the Kirby-Lodi-Rea cluster and the newly expanded Sonic Zone. These targets exhibit large-scale alteration footprints and high-grade copper mineralization at surface, making them prime candidates for near-term exploration and development."

To view the full article, visit https://ibn.fm/60keS

Torr Metals Inc. (TSX.V: TMET) operates as a mineral exploration company focusing on the identification, acquisition, and advancement of mineral properties. With full 100% ownership of over 1,000 square kilometers of gold and copper projects strategically positioned in premier low-cost mining jurisdictions, Torr is poised for substantial returns across various promising regions.

The company’s extensive portfolio encompasses multiple district-scale projects, including the Filion Gold Project in northern Ontario, the Kolos Copper-Gold Project in south-central British Columbia, and the Latham Copper-Gold Project in northern British Columbia. These projects are all located in prolific mining regions with paved highway access, robust support infrastructure, and favorable geological conditions offering significant potential for new discoveries.

Headquartered in Vancouver, British Columbia, Torr Metals is ideally situated to leverage its expertise and resources for continued exploration and growth.

Projects

Kolos Copper-Gold Project

Situated within British Columbia’s prime copper-producing belt, the 140-square-kilometer Kolos Copper-Gold Project exhibits Nicola Belt geology similar to notable porphyry mines, including Copper Mountain and Highland Valley, respectively situated 106 kilometers to the south and 30 kilometers to the northwest.

With field operations based in the nearby city of Merritt and year-round access provided via Highway 5, the Kolos Project showcases substantial discovery upside potential with five defined large-scale copper-gold-molybdenum anomalies untested by drilling.

Torr Metals’ primary focus lies in unlocking the potential for major new discoveries at the Kolos Copper-Gold Project, with recent surface geochemical results marking a significant milestone positioning the company as a new key player in the region.

Filion Gold Project

The 261-square-kilometer Filion Project is situated within a largely unexplored greenstone belt where gold was initially discovered in the 1930s. With a comparable geological setting to regional orogenic gold deposits and multiple newly identified and undrilled gold trends in surficial geochemistry, the Filion Project holds significant district-scale exploration promise.

The Filion Project benefits from unparalleled infrastructure access, with direct drive-on access from the Trans-Canada Highway, as well as a regional railway and power grid four kilometers to the south. Additionally, the nearby town of Kapuskasing, with a population of 8,300, provides essential support services.

This strategic positioning ensures the Filion Project’s viability for cost-effective, year-round operations in an area poised for untapped discovery potential.

Latham Copper-Gold Project

Situated in British Columbia’s renowned Golden Triangle, the Latham Project spans a vast 689-square-kilometer district, offering immense potential for multiple major discoveries. Accessible year-round via Highway 37, just 20 kilometers south of the town of Dease Lake, the site is strategically located amidst established mining infrastructure, including the active Red Chris mine to the southeast and upcoming major porphyry projects at Schaft Creek and Galore Creek along-trend to the southwest.

Highlighted by the Gnat Pass copper-gold porphyry deposit dating back to the 1960s, the Latham Project presents a compelling opportunity for significant expansion and potential discovery. A non-compliant indicated resource at the Gnat Pass deposit includes 33 million tonnes at 0.39% copper, open beyond 200 meters vertical depth, alongside six drill-ready kilometer-scale copper-gold exploration targets.

Moreover, the Latham Project’s appeal corresponds to the region being an attractive destination for major asset acquisitions and takeovers. Recent transactions within a 40-kilometer radius include Newmont’s 2021 acquisition of the Saddle North copper-gold porphyry deposit for $311 million and Newcrest’s investment in the Red Chris copper-gold porphyry deposit in 2019 for $804 million, underscoring industry acknowledgment of the region’s potential.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 that the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

Likewise, a report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Malcolm Dorsey, P.Geo., is President, CEO and Director of Torr Metals. He brings over a decade of expertise as a seasoned exploration geologist and project developer, having been pivotal in driving the success of numerous diverse projects across North, Central, and South America. His comprehensive background spans early-stage exploration through to resource development and project acquisitions. His academic credentials include an M.Sc. in Geology and Geophysics from the University of Calgary, where his research characterized the district-scale structural influences affecting copper and gold mineralizing events in western British Columbia. Prior to his current role, he served as Senior Geologist for Benchmark Metals, where his contributions were instrumental in advancing the company’s gold equivalent resource from approximately 80,000 ounces to a maiden resource estimate of 2.92 million ounces.

John Williamson, P. Geol., is Chairman and Director of Torr Metals. He is a mining executive and investor with more than 30 years of experience as a founder, promoter and leader in the formation, financing and operation of private and public companies with exploration and mining interests worldwide. On more than one occasion his team’s efforts have been recognized for excellence by being named to the TSX Venture 50. He holds a B.Sc. in Geology and is a registered Professional Geologist (P.Geol.) with the Association of Professional Engineers and Geoscientists (APEGA) and the Geological Association of Canada.

Torr Metals Inc. (TSX.V: TMET), closed Monday's trading session at $0.11, off by 18.5185%, on 1,000 volume. The average volume for the last 3 months is 2,440 and the stock's 52-week low/high is $0.04/$0.195.

Recent News

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

The QualityStocks Daily Newsletter would like to spotlight Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

America is facing threats of infectious diseases on multiple fronts; cases of measles are escalating in Texas and the surrounding states, bird flu is spreading across the country, and cases of polio and Ebola abroad pose an added risk to Americans due to international travel. Amid all these threats of infectious diseases, the U.S. CDC is experiencing mass layoffs and a great deal of uncertainty triggered by Trump's efforts to downsize federal health agencies and reduce government spending. The firings have put a strain on personnel numbers within the CDC and it is getting harder to respond appropriately to any disease outbreak. Doctor Deblina Datta, who worked for 24 years as a physician specializing in infectious diseases at the CDC and is now retired, says she has never seen staff morale at the CDC so low as it currently is, and yet this morale hit is coming at a time when workers are faced with several disease outbreaks they need to address. Concerns about vaccine policy changes at the federal government level have caused the CDC to postpone a scheduled meeting of vaccine advisors. The CDC also suspended an advertising campaign promoting flu vaccination, and this happened at a time when the country was facing an unprecedented flu outbreak not seen in a long time. How soon will stability return to the CDC and other health agencies? Only time will tell, but the cost in terms of inadequate disease response could be high. The policy-level disruptions could end up having negative effects on efforts by firms like Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) aimed at developing immune therapies targeting many of the infectious diseases that are emerging or reemerging not just in the U.S. but around the world.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, Scinai is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. Scinai is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, Scinai has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, Scinai signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. Scinai anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of Scinai’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

Scinai has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, Scinai will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. Scinai anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

CDMO Services

While NanoAb pipeline development is Scinai’s core focus, the company also offers its cGMP manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for contract development and manufacturing organization (CDMO) services. This offering is designed to keep the Scinai team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb pipeline development.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future Scinai drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is Scinai’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at Scinai. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at Scinai. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining Scinai, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at Scinai. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to Scinai through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), closed Monday's trading session at $3.54, up 0.0961375%, on 1,969 volume. The average volume for the last 3 months is 17,438 and the stock's 52-week low/high is $2.23/$8.92.

Recent News

Nightfood Holdings Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (OTCQB: NGTF).

Nightfood Holdings (OTCQB: NGTF) , a leader in AI-powered robotic solutions for the hospitality industry, provided an update on its merger and acquisition strategy, highlighting key acquisitions and targets for 2025. The company has secured assets exceeding $40 million in total value, including the completed acquisition of Future Hospitality Ventures for $2 million in an all-share exchange. Pending acquisitions include SWC Group Inc. for $10 million, an undisclosed robotics firm, and a globally branded full-service hotel in Southern California valued between $32 million and $38 million. These deals aim to strengthen Nightfood's capabilities in robotic automation, food service packaging, and hospitality real estate. Chairman Jamie Steigerwald emphasized the company's commitment to integrating robotics with hospitality to drive long-term growth and operational efficiency.

To view the full press release, visit https://ibn.fm/KPBCw

Nightfood Holdings Inc. (OTCQB: NGTF) is a visionary holding company focused on identifying and capitalizing on explosive market trends within hospitality, food services and consumer packaged goods. By leading newly emerging categories and seizing opportunities in markets undergoing transformational upheaval, the company’s mission is to create unparalleled upside potential in industries ripe for innovation and growth.

Subsidiaries

Nightfood Inc.

The company’s flagship subsidiary, Nightfood Inc., is changing the way the world snacks at night. Humans are biologically hard-wired to crave sweets and fats at night – a survival mechanism from our hunter-gatherer days. Modern consumers know bingeing excess calories before the long nightly fast is no longer necessary for survival, but exploding screen time and decreased willpower at night results in over 90% of American adults snacking between dinner and bed every week, contributing to an estimated one billion nighttime snack occasions weekly (according to SleepFoundation.org).

The most popular choices – ice cream, cookies, chips and candy – are not only unhealthy but also impair sleep quality due to their nutritional profiles. Nightfood snacks are uniquely formulated by sleep and nutrition experts to satisfy nighttime cravings AND support better sleep.

Market Opportunity

Euromonitor International projects the American snack market will grow from $150 billion in 2022 to $170 billion in 2027. Snacking between dinner and bed is estimated to account for over $60 billion annually, creating an opportunity for a multi-billion-dollar sub-category to emerge in the coming years: sleep-friendly snacking.

Nightfood is the brand pioneering that category.

Nightfood’s innovation has led to partnership overtures from global giants, including the largest food and beverage company in the world, Nestlé, with whom Nightfood completed a “test-and-learn” joint initiative in 2023.

Management believes that successfully scaling Nightfood’s 2024 direct-to-consumer launch of sleep-friendly cookies will bring the category to life, opening the door for partnerships with and potential acquisition by global snack giants seeking to lead this potential billion-dollar emerging sub-category.

Future Hospitality Ventures Holdings Inc. (d/b/a roboOp365)

Future Hospitality Ventures Holdings, operating under the brand roboOp365, is revolutionizing the hospitality industry with cutting-edge automation and robotic solutions.

roboOp365 enhances operational efficiency and guest experiences through innovative technologies, including automated culinary bot, server robots and AI-enhanced applications. roboOp365 helps hospitality providers reduce costs, streamline operations and deliver superior service by integrating these advancements.

Market Opportunity

The robots-as-a-service (RaaS) business model has gained significant traction, super-charged by the COVID-19 pandemic, which instantly catalyzed game-changing growth and application. According to Verified Market Research, the service robotics market is projected to reach $173.17 billion by 2030, growing at a compound annual growth rate (CAGR) of 21.25%. Compared to Asia, the United States market is in the early stages of adopting these technologies, but acceptance is accelerating aggressively.

Several factors are driving this trend. Key industries such as hotels and restaurants are still struggling to rebound from the pandemic’s impact, hoping to return to pre-pandemic levels, if possible. Such recovery will largely be dependent upon service robots. In California specifically, factors such as rising labor costs, more rigorous labor laws and ongoing high turnover rates in labor-intensive sectors make it impossible for businesses to survive, thrive and compete without robotics.

Innovation Across Sectors

Nightfood Holdings Inc. is dedicated to driving innovation across its focus sectors of food services, automation and hospitality applications. In food services, the company leverages automation technology to drive operational efficiency for operators while meeting evolving consumer needs. In the hospitality industry, it’s deploying solutions that redefine guest experiences. Nightfood’s consumer-packaged goods initiatives are key to breakthrough trends in health and wellness.

Synergizing Food and Technology

The synergy of food and technology within Nightfood Holdings Inc. creates a holistic approach to innovation and automation. By integrating these areas, the company offers comprehensive solutions that address multiple facets of market needs. Its automation and artificial intelligence solutions in food service and hospitality create a seamless and enhanced consumer experience.

Through this integrated approach, Nightfood Holdings Inc. not only meets current market demands but also anticipates and influences future trends, positioning itself as a leader in innovation across these interconnected sectors. Synergies in these related and explosive categories result in operational efficiency and benefits for the company’s customers and partners and outsized upside and opportunity for its investors.

Management Team

Sean Folkson is the Chairman and President of Nightfood. He founded Nightfood when he couldn’t find a solution to his nighttime snacking problem. Recognizing the growing body of research linking nutritional intake with sleep quality, he launched the first snack brand specifically formulated to give consumers better, healthier and more sleep-friendly snacks for that peak-cravings slot between dinner and bed. He is a serial entrepreneur and problem-solver, having previously founded Specialty Equipment Direct, an online distributor of floor removal equipment, and AffiliatePros.com, a pioneering company in online affiliate marketing.

Lei Sonny Wang is the CEO of Nightfood Holdings. He is a strategist and business driver for early-stage and growth-stage companies. He is the founder and former CEO of Future Hospitality Ventures Holdings Inc., which was acquired by Nightfood Holdings Inc. At Future Hospitality, he leveraged his significant international business development experience into distribution relationships with leading global robotics manufacturers. At Nightfood, he is working to grow revenue and improve performance and profitability across all subsidiaries.

Nightfood Holdings Inc. (OTCQB: NGTF), closed Monday's trading session at $0.008505, off by 1.1047%, on 127,767 volume. The average volume for the last 3 months is 126,120 and the stock's 52-week low/high is $0.0053/$0.035.

Recent News

Annovis Bio Inc. (NYSE: ANVS)

The QualityStocks Daily Newsletter would like to spotlight Annovis Bio Inc. (NYSE: ANVS).

Annovis Bio Inc. Overview

Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as AD and PD. Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach addresses both the cognitive decline in AD and the motor dysfunction in PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly known as Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a 3.3 point improvement compared to 0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating buntanetap’s mechanism of action.

Similarly, in the recently completed Phase III study of buntanetap in patients with early PD, buntanetap significantly improved disease-related daily non-motor and motor functions in Parkinson’s patients who had a diagnosis over 3 years as well as improved cognition in all PD patients. It further underscores buntanetap’s potential as a transformative therapy.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (AD), a figure projected to rise to almost 13 million by 2050​ (Alzheimer’s Association)​​ (Republican Policy Committee)​. Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease​ (SingleCare)​.

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050​​. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

  • Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients.
  • Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients.
  • Groundbreaking Clinical Insights: Recent Phase III data in Parkinson’s Disease patients demonstrates significant improvements in motor and cognitive functions.
  • Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate buntanetap’s disease-modifying potential.
  • Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s.

Management Team

  • Maria L. Maccecchini, Ph.D. – Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.
  • Cheng Fang, Ph.D. – Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.
  • Michael Christie, Ph.D. – VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.
  • Melissa Gaines – Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.
Recent Achievements

Annovis Bio continues to advance its mission of developing transformative therapies for neurodegenerative disorders. The company recently announced statistically significant data from its Phase II/III Alzheimer’s study, demonstrating the potential of its lead drug candidate, buntanetap, to improve cognition in patients with early Alzheimer’s Disease (AD). Additionally, the company has released promising data from its Phase III study of buntanetap in patients with early Parkinson’s Disease (PD), which highlights significant advancements in both cognitive and motor functions. These milestones underscore the expanding therapeutic reach of buntanetap.

Investment Considerations
  • Unique Market Position: Annovis Bio is uniquely positioned as the only company developing a drug for both AD and PD that inhibits multiple neurotoxic proteins simultaneously.
  • Strong Clinical Results: Buntanetap’s Phase II/III data shows significant cognitive improvement in early AD patients, and the recent Phase III data in PD patients further validates its broad therapeutic potential.
  • Strategic Growth Plans: With recent successful trial results, Annovis Bio is poised for future growth, supported by strong patent protections and upcoming clinical trials.
  • Significant Market Need: As the prevalence of neurodegenerative diseases continues to rise, the demand for effective treatments like buntanetap remains critical.

Annovis Bio continues to advance its mission of developing transformative therapies for neurodegenerative disorders. The company recently announced statistically significant data from its Phase II/III Alzheimer’s study, demonstrating the potential of its lead drug candidate, buntanetap, to improve cognition in patients with early Alzheimer’s Disease (AD). Additionally, the company has released promising data from its Phase III study of buntanetap in patients with early Parkinson’s Disease (PD), which highlights significant advancements in both cognitive and motor functions. These milestones underscore the expanding therapeutic reach of buntanetap.

Annovis Bio Inc. (NYSE: ANVS), closed Monday's trading session at $1.83, up 2.2346%, on 5,722 volume. The average volume for the last 3 months is 681,308 and the stock's 52-week low/high is $1.67/$20.

Recent News

SuperCom Ltd. (NASDAQ: SPCB)

The QualityStocks Daily Newsletter would like to spotlight SuperCom Ltd. (NASDAQ: SPCB) .

SuperCom Ltd. (NASDAQ: SPCB) provides secured solutions for the e-government, IoT and cybersecurity sectors. Since 1988, the company has been a trusted global provider of traditional and digital identity offerings, providing cutting-edge electronic and digital security solutions to governments and organizations, both private and public, around the world.

SuperCom’s mission is to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services.

The company is headquartered in Tel Aviv, Israel, with offices in California and other regions in the U.S.

Business Units

IoT and Connectivity

SuperCom IoT products and solutions provide advanced electronic monitoring solutions and services to criminal justice agencies, enabling customers to detect unauthorized movement of people, vehicles, and other monitored objects. The company provides an all-in-one, field-proven PureSecurity offender monitoring suite, accompanied by services such as GPS monitoring, home detention, domestic violence prevention, and more. The company’s services are specifically tailored to meet each client’s needs.

SuperCom’s proprietary Puresecurity suite of hardware, connectivity, and software components is the foundation for its criminal justice services and offerings. SuperCom is leveraging its extensive technology expertise to implement groundbreaking artificial intelligence (AI) technologies into various parts of its core offerings. By leveraging the power of AI, SuperCom’s PureSecurity platform can offer new abilities, such as amplified data analysis, predictive modeling, and streamlined automation – all geared toward optimizing decision-making and operational efficiency.

Competitive advantages of SuperCom’s technology include:

  • Long Battery Life (No Tag Charging Required)
  • Ultra Lightweight Form Factor
  • Next-Gen Location Tech
  • Protection of Domestic Violence Victims
  • And More

 

Cybersecurity

In 2015, SuperCom identified the cybersecurity market as a fast-growing space with significant advantages due to synergistic technologies and a shared customer base with its e-Gov and IoT business units. Consequently, SuperCom strategically acquired Prevision Ltd., a company with a strong presence in the market and a broad range of competitive cybersecurity services.

During the first quarter of 2016, SuperCom acquired Safend Ltd., an international provider of cutting-edge endpoint data protection guarding against corporate data loss and theft through content discovery and inspection, encryption methodologies, and comprehensive device and port control.

Both acquisitions significantly expanded the breadth of the company’s global cybersecurity capabilities.

e-Gov

Through proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has helped governments, and national agencies design and issue secured multi-identification, or Multi-ID, documents and robust digital identity solutions to their citizens, visitors, and lands.

The company has focused on expanding its activities in the traditional identification, or ID, and electronic identification, or e-Gov, markets, including the design, development, and marketing of identification technologies and solutions to governments in Europe, Asia, America, and Africa using SuperCom’s e-Government platforms.

Market Opportunity

Data from Berg Insight estimates the market for electronic monitoring solutions will grow from $1.2 billion in 2021 to $2.1 billion in 2026, marking a CAGR of 10.8% for the forecast period.

High recidivism rates, prison overcrowding, and soaring incarceration costs are some factors that are driving the electronic monitoring of offenders’ market growth.

An analysis by ReportLinker forecasts that the global cybersecurity market will grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, achieving a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving the cybersecurity market growth.

Management Team

Ordan Trabelsi is President and CEO of SuperCom. He has over 15 years of experience as CEO, growing high-tech companies globally. He also has experience in research and development and product innovation, as well as hands-on experience in cybersecurity, encryption, advanced mathematics, and mobile and internet network technologies. Prior to joining SuperCom, he served as co-founder and CEO of Klikot Inc., a global social networking company. He holds an MBA from Columbia University and a B.Sc. in Computer Engineering from The Technion: Israel Institute of Technology.

Barak Trabelsi is COO of SuperCom. He has expertise in big data, cyber, mobile, and internet network technologies, as well as extensive experience in product development and strategies. Prior to joining SuperCom, he served as Senior Product Manager at Equinox Ltd. Before that, he served for four years as VP of R&D at Sigma Wave, a wireless, security, and internet-focused company. He holds a B.Sc. in Computer Science and Business, as well as an MBA from Tel Aviv University.

Gil Alfi is VP of Sales at Safend Ltd., SuperCom’s cybersecurity subsidiary. He joined SuperCom in 2016 as VP of Business Development for Safend. He has more than 18 years of experience in technology companies. He served as an R&D team technology lead for more than seven years and as Director of Product Management for various telecom and wireless companies for more than 10 years. Prior to joining SuperCom, he served as Regional Sales Director at Safend, managing sales regions in Europe and Africa. He holds a B.Sc. in Computer Science and Mathematics and an M.Sc. in Computer Science from Bar-Ilan University.

SuperCom Ltd. (NASDAQ: SPCB), closed Monday's trading session at $8.93, up 2.9988%, on 3,449 volume. The average volume for the last 3 months is 371,559 and the stock's 52-week low/high is $2.55/$18.95.

Recent News

Thumzup Media Corp. (NASDAQ: TZUP)

The QualityStocks Daily Newsletter would like to spotlight Thumzup Media Corp.(NASDAQ: TZUP).

Thumzup Media Corp. (NASDAQ: TZUP) is at the forefront of modernizing the social media branding and marketing industry with its unique platform designed to connect advertisers directly with everyday social media users. The company’s mission is to empower individuals by turning their authentic social media activity into a monetizable asset while providing brands with cost-effective and impactful advertising solutions.

Through its flagship Thumzup platform, the company offers a seamless system where users post about participating advertisers and receive cash payments via Venmo or PayPal. Thumzup recently announced plans to integrate bitcoin as an additional payment option, expanding accessibility for gig economy workers.

By prioritizing accessibility and transparency, Thumzup is redefining traditional marketing strategies with an inclusive, user-driven approach. It is leveraging its scalable technology to disrupt the status quo, offering a win-win ecosystem for advertisers and users alike.

The company is headquartered in Los Angeles, California.

Products

Thumzup’s key offering, the Thumzup platform, features two integrated components: a sophisticated advertiser dashboard and an intuitive consumer-facing app. The advertiser dashboard provides companies with tools to design, manage, and analyze campaigns.

On the consumer side, the Thumzup app allows users to participate in campaigns by posting approved content to their social media accounts. In exchange, users receive direct cash rewards.

Recent enhancements to the platform include the launch of video capabilities, enabling integration with Instagram Reels. This update allows advertisers to tap into the growing popularity of short-form video content, broadening campaign possibilities.

The platform not only incentivizes users but also delivers authentic, relatable content for advertisers, bridging the gap between grassroots engagement and effective campaign management.

Market Opportunity

The global social media advertising market is projected to reach $219.8 billion in 2024, with an expected annual growth rate of 3.86%, resulting in a market volume of $255.8 billion by 2028, according to Statista. Thumzup targets the intersection of this growth with the rise of micro-influencers and everyday social media users, a segment that remains largely untapped in the advertising ecosystem.

In October 2024, Thumzup achieved 202% year-over-year growth in advertisers on its proprietary platform, demonstrating significant traction and scalability. With plans for further expansion in both advertiser partnerships and user engagement, the company is well-positioned to capitalize on the growing demand for authentic and trust-building marketing strategies. As Thumzup integrates innovative features like video support and continues its geographic expansion, it is poised to capture a larger share of the rapidly growing social media advertising market.

Leadership Team

Robert Steele, Founder and Chief Executive Officer of Thumzup, has over 25 years of experience as a technologist and entrepreneur. He has successfully launched multiple companies, including iBrite, a pioneer in mobile software development. Mr. Steele’s leadership and innovative vision drive Thumzup’s mission to democratize the social media marketing industry.

Robert Haag, Director of Thumzup, is the Managing Member of Westside Strategic Partners LLC and a Managing Director at IRTH Communications. With decades of experience in financial communications, investment, and corporate strategy, Mr. Haag provides critical guidance on strategic initiatives and business growth.

Dr. Joanna Massey, member of the company’s Board of Advisors, brings over 25 years of executive experience with Fortune 500 companies and startups to Thumzup. She has held senior roles in communications at Lions Gate Entertainment and CBS Corporation. Dr. Massey leverages her expertise to support Thumzup’s growth strategy.

Thumzup Media Corp. (NASDAQ: TZUP), closed Monday's trading session at $3.17, up 3.9344%, on 1,109 volume. The average volume for the last 3 months is 228,423 and the stock's 52-week low/high is $2.02/$7.89.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.